Plain-English translation of NCT06988475 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called in adults with cancers that have specific changes in a gene called MET. These can be rare cancers or common cancers where this particular genetic change is uncommon. The goal is to see if this medication, which targets these specific genetic changes, can help shrink or control these cancers.
Many cancers have specific genetic changes that can be targeted with specialized medications. This trial exists to find out whether this medication works for patients whose cancers have MET gene changes, so that patients with these rare or unusual cancers have more treatment options available.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital or clinic for screening, including a tissue biopsy and blood tests. If you qualify, you would take the medication by mouth until your cancer improves, stops responding, or side effects become too difficult. You would have regular blood samples taken during treatment and follow-up visits every 3 months for 2 years after you stop the medication.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United Kingdom